

Amedisys U.S. Settlement Left Some Concerns Unresolved, Shows Flexibility on Remedies

MEDIA MENTIONS | LESS THAN 1 MIN READ

August 14, 2025


By: Ilana Kowarski and Flavia Fortes

MLex

Axinn managing partner [Jeny Maier](#) was quoted in the *MLex* article, “Amedisys U.S. Settlement Left Some Concerns Unresolved, Shows Flexibility on Remedies.”

Click [here](#) to access the publication. A subscription is required.

Related People



Jeny M. Maier

Related Services

To subscribe to our publications, [click here](#).

Featured Insights

- LegalNEXT 2025
SPEAKING ENGAGEMENT ANTITRUST
- Informa Antitrust Texas 2025
SPEAKING ENGAGEMENT ANTITRUST
- ACI Forum on Pharma & Biotech Patent Litigation USA 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- MCCA Gala 2025
SPONSORSHIP ANTITRUST
- Centerforce IP Strategy Summit: Palo Alto
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Consero Healthcare General Counsel Forum 2025
SPEAKING ENGAGEMENT ANTITRUST
- CCWC 21st Annual Career Strategies Conference
SPEAKING ENGAGEMENT
- Pro Bono Partnership 28th Anniversary Gala
SPONSORSHIP ANTITRUST
- Ronald McDonald House New York Together in Gold Annual Gala
SPONSORSHIP ANTITRUST
- How Justices' Ruling Upends Personal Jurisdiction Defense
BYLINE ARTICLES LITIGATION & TRIALS

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved